



Updated Efficacy and Safety of Taletrectinib in Patients With ROS1+ Non-Small Cell Lung Cancer: The Global TRUST-II Study

Geoffrey Liu,¹ Chang-Min Choi,² Shunichi Sugawara,³ Noriko Yanagitani,⁴ Filippo De Braud,⁵ Jorge Nieva,⁶ Misako Nagasaka,⁷ Caicun Zhou,⁸ Enriqueta Felip,⁹ Xianyu Zhang,¹⁰ Wei Wang,¹⁰ Nathan A. Pennell,¹¹ Maurice Pérol,¹² Lyudmila Bazhenova¹³

¹Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, Canada; ²Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea; ³Sendai Kousei Hospital, Miyagi, Japan; ⁴The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan; ⁵University of Milan, Milan, Italy; ⁶Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA; ⁷University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, CA, USA; ⁸Department of Medical Oncology, Shanghai East Hospital and Thoracic Cancer Institute, Tongji University School of Medicine, Shanghai, China; ⁹Vall d'Hebron University Hospital, Barcelona, Spain; ¹⁰Nuvation Bio, New York, NY, USA; ¹¹Cleveland Clinic Taussig Cancer Institute, Cleveland, OH, USA; ¹²Léon Bérard Cancer Center, Lyon, France; ¹³University of California San Diego Moores Cancer Center, San Diego, CA, USA

TRUST-II^a: Phase 2 Trial of Taletrectinib in ROS1+ NSCLC






Baseline Characteristics	TKI-naïve (n=55) ^c	TKI-pretreated (n=50) ^c	Safety Population (N=171) ^e
Median age, years (range)	57.0 (27–83)	55.5 (27–79)	57.0 (27–83)
Female, n (%)	31 (56.4)	27 (54.0)	96 (56.1)
Never smoker, n (%)	28 (50.9)	30 (60.0)	95 (55.6)
Region: Asia / non-Asia, n (%)	34 (61.8) / 21 (38.2)	22 (44.0) / 28 (56.0)	74 (43.3) / 97 (56.7)
ECOG PS: 0 / 1, n (%)	22 (40.0) / 33 (60.0)	24 (48.0) / 26 (52.0)	70 (40.9) / 101 (59.1)
Stage IV disease, n (%)	49 (89.1)	49 (98.0)	162 (94.7)
Prior chemotherapy, n (%)	11 (20.0)	19 (38.0)	67 (39.2)
Brain metastases at baseline, ^d n (%)	19 (34.5)	28 (56.0)	78 (45.6)
Prior crizotinib / entrectinib, n (%)	-	40 (80.0) / 10 (20.0)	86 (50.3) / 29 (17.0)

Data cutoff: October 28, 2024. c, confirmed; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group performance status; IC, intracranial; IRC, independent review committee; (m)RECIST v1.1, (modified) Response Evaluation Criteria In Solid Tumors version 1.1; NSCLC, non-small cell lung cancer; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; QD, once daily; TKI, tyrosine kinase inhibitor; TTR, time to response.
^aNCT04919811. ^bOr ≥20 years, as required by local regulations. ^cRegistrational cohorts are shown. ^dAssessed by IRC per mRECIST v1.1. ^eSafety population includes all patients who received ≥1 dose of taletrectinib 600 mg.

Taletrectinib: Efficacy Outcomes in TKI-naïve ROS1+ NSCLC

TKI-naïve (n=54)^{a,b}
Median follow-up: 20.5 mo (range: 8.3–34.5)






Efficacy	TKI-naïve (n=54)
cORR: prior chemo, yes / no, n/N (%)	9/10 (90.0) / 37/44 (84.1)
Median TTR, ^c mo (95% CI)	1.4 (1.3–1.4)
IC efficacy	(n=9) ^d
IC-ORR, % (95% CI)	66.7 (29.9–92.5)

Data cutoff: October 28, 2024. BOR, best overall response; CI, confidence interval; CR, complete response; mo, months; NE, not evaluable; NR, not reached; PD, progressive disease; PR, partial response; SD, stable disease.
^aResponse evaluable population includes patients with ≥1 measurable lesion at baseline who received ≥1 dose of taletrectinib. ^bOne patient with cBOR of NE is not shown in the waterfall plot. ^cTTR and DOR reported in responders only.
^dPatients with ≥1 measurable brain metastasis at baseline. *One patient with cBOR of SD had a best percent change of 0%.

Taletrectinib: Efficacy Outcomes in TKI-pretreated ROS1+ NSCLC

TKI-pretreated (n=47)^a
Median follow-up: 20.4 mo (range: 8.6–34.5)



Efficacy	TKI-pretreated (n=47)
cORR: prior chemo, yes / no, n/N (%)	15/19 (78.9) / 14/28 (50.0)
Median TTR, ^c mo (95% CI)	1.4 (1.4–1.6)
IC efficacy	(n=16) ^d
IC-ORR, % (95% CI)	56.3 (29.9–80.3)

Data cutoff: October 28, 2024. ^aResponse evaluable population includes patients with ≥1 measurable lesion at baseline who received ≥1 dose of taletrectinib. ^bAll other patients received prior crizotinib. ^cTTR and DOR reported in responders only. ^dPatients with ≥1 measurable brain metastasis at baseline. *One patient with cBOR of SD had a best percent change of 0%.

Taletrectinib Safety: TEAEs in ≥15% of Patients (N=171)^a

Patients, n (%)	Any grade	Grade ≥3
Any TEAEs	169 (98.8)	90 (52.6)
Most frequent TEAEs (≥15% of patients)		
Increased ALT	115 (67.3)	26 (15.2)
Increased AST	112 (65.5)	12 (7.0)
Diarrhea	99 (57.9)	1 (0.6)
Nausea	89 (52.0)	3 (1.8)
Vomiting	59 (34.5)	2 (1.2)
Constipation	41 (24.0)	0
Anemia	34 (19.9)	7 (4.1)
Increased blood CPK	34 (19.9)	6 (3.5)
Dysgeusia	33 (19.3)	0
Dizziness	30 (17.5)	0
Electrocardiogram QT prolonged	28 (16.4)	6 (3.5)
Decreased appetite	26 (15.2)	1 (0.6)

- With 5 months of additional follow-up,¹ no new safety signals were identified
- Rates of neurologic TEAEs were low and limited to Grade 1 or 2
 - **Dysgeusia:** 15.2% Grade 1; 4.1% Grade 2
 - **Dizziness:** 15.2% Grade 1; 2.3% Grade 2
- **2.3%** of patients discontinued treatment due to treatment-related AEs
 - No patients in TRUST-II discontinued treatment due to increased ALT or AST

Data cutoff: October 28, 2024. AE, adverse event; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; TEAE, treatment-emergent adverse event.

^aSafety population includes all patients who received ≥1 dose of taletrectinib 600 mg. Median exposure to taletrectinib was 9.7 mo (range: 0.2–31.8).

1. Liu G, et al. *J Thorac Oncol.* 2024;19:S72–S73.

Conclusions

- In the global **TRUST-II study**, taletrectinib demonstrated **high overall and IC response rates** in both TKI-naïve and TKI-pretreated patients with advanced ROS1+ NSCLC
- With 5 months of additional follow-up,¹ **responses remained durable with encouraging PFS**; OS remained immature
- Taletrectinib demonstrated a **favorable safety profile**, with low rates of neurologic AEs and treatment discontinuations
- Post-FDA approval,² these results further support taletrectinib as an effective treatment option for patients with advanced ROS1+ NSCLC, regardless of prior TKI exposure

Other presentations on taletrectinib at WCLC 2025

Tuesday 9 September 10:00 AM – 11:30 AM (Poster Session)

TRUST-I study update (P3.12.69), TRUST-III trial in progress (P3.18.62), Clinical pharmacologic characteristics (P3.12.12)

1. Liu G, et al. *J Thorac Oncol*. 2024;19:S72–S73. 2. IBTROZI™ (taletrectinib). Prescribing Information. Nuvation Bio Inc.; 2025.



Acknowledgments

- We would like to thank all patients who participated in this study, the study investigators, and their staff
- This study was sponsored by Nuvation Bio Inc.
- Medical writing support was provided by Flaminia Fenoaltea, MSc, of Ashfield MedComms, an Inizio company, and was funded by Nuvation Bio Inc.